Sun Pharmaceutical Industries Limited announced the company will share 19 abstracts, including new clinical data, across its dermatology and immunology portfolio, at 2026 Winter Clinical Miami on February 27-March 1, 2026 in Aventura, Florida. The data presentations will include study results for several medications, including LEQSELVI®? (tildrakizumab-asmn), WINLEVI®?
(clascosterone cream 1%) and LEQSELVI?? (deuruxolitinib). ILUMYA data to be presented at the conference include new real-world analyses examining biologic use and continuity of care in patients with moderate-to-severe plaque psoriasis, including older and clinically complex patient populations.
Additional presentations evaluate real-world effectiveness and patient-reported outcomes across prior biologic experience and U.S. geographic regions, providing practical insight into treatment performance in routine dermatology practice. New, open-label, 52-week data from a pilot study evaluating WINLEVI in patients with skin of color demonstrated sustained improvement in acne severity with a consistent safety and tolerability profile, reinforcing WINLEVI as an appropriate option across the diversity of patients age 12 and older with acne vulgaris. In addition, pilot combination studies show that incorporating WINLEVI into multimodal acne treatment regimens provides benefit, further supporting its usage as a part of a regimen with other acne therapies.
Notably, 10 abstracts include data showing that LEQSELVI enables early and sustained scalp hair regrowth in severe alopecia areata, with consistent benefits across key subgroups, including those with varying disease durations and eyebrow, eyelash and nail involvement. Additional findings from the company's landmark alopecia areata survey illuminate discrepancies between patient and clinical perspectives, particularly as it relates to clinical priorities, treatment awareness, and goal prioritization.
